Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerald L Denardo

Showing results (21-30 of 63) with videos related to

Pageof 7
Sort By:
Cancer Biotherapy & Radiopharmaceuticals|March 28, 2002
Radiation dosimetry for radionuclide therapy in a nonmyeloablative strategyGerald L DeNardo, Christine L Hartmann Siantar, Sally J DeNardo
Cancer Biotherapy & Radiopharmaceuticals|July 26, 2002
Treatment planning for molecular targeted radionuclide therapyChristine Hartmann Siantar, Kai Vetter, Gerald L DeNardo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2003
Documentation of idiotypic cascade after Lym-1 radioimmunotherapy in a patient with non-Hodgkin's lymphoma: basis for extended survival?Bonnie M Bradt, Sally J DeNardo, Gary R Mirick, et al.
Cancer Immunology, Immunotherapy : CII|April 18, 2003
Human antiglobulin response to foreign antibodies: therapeutic benefit?Gerald L DeNardo, Bonnie M Bradt, Gary R Mirick, et al.
Clinical Lymphoma|October 23, 2004
Radiometals as payloads for radioimmunotherapy for lymphomaGerald L DeNardo, Stephen J Kennel, Jeffry A Siegel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2005
Direct antilymphoma effects on human lymphoma cells of monotherapy and combination therapy with CD20 and HLA-DR antibodies and 90Y-labeled HLA-DR antibodiesGerald L DeNardo, Evan Tobin, Kaylund Chan, et al.
Bioconjugate Chemistry|January 20, 2005
Characterization of site-specific ScFv PEGylation for tumor-targeting pharmaceuticalsArutselvan Natarajan, Cheng-Yi Xiong, Huguette Albrecht, et al.
Cancer Biotherapy & Radiopharmaceuticals|February 27, 2008
Development of multivalent radioimmunonanoparticles for cancer imaging and therapyArutselvan Natarajan, Cheng-Yi Xiong, Cordula Gruettner, et al.
Bioconjugate Chemistry|March 22, 2007
Synthesis and radiolabeling of selective high-affinity ligands designed to target non-Hodgkin's lymphoma and leukemiaSaphon Hok, Arutselvan Natarajan, Rod Balhorn, et al.
Protein Engineering, Design & Selection : PEDS|June 9, 2006
Development of tumor targeting anti-MUC-1 multimer: effects of di-scFv unpaired cysteine location on PEGylation and tumor bindingCheng-Yi Xiong, Arutselvan Natarajan, Xu-Bao Shi, et al.
Pageof 7

Showing results (21-30 of 63) with videos related to

Sort By:
Pageof 7
Cancer Biotherapy & Radiopharmaceuticals|March 28, 2002
Radiation dosimetry for radionuclide therapy in a nonmyeloablative strategyGerald L DeNardo, Christine L Hartmann Siantar, Sally J DeNardo
Cancer Biotherapy & Radiopharmaceuticals|July 26, 2002
Treatment planning for molecular targeted radionuclide therapyChristine Hartmann Siantar, Kai Vetter, Gerald L DeNardo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2003
Documentation of idiotypic cascade after Lym-1 radioimmunotherapy in a patient with non-Hodgkin's lymphoma: basis for extended survival?Bonnie M Bradt, Sally J DeNardo, Gary R Mirick, et al.
Cancer Immunology, Immunotherapy : CII|April 18, 2003
Human antiglobulin response to foreign antibodies: therapeutic benefit?Gerald L DeNardo, Bonnie M Bradt, Gary R Mirick, et al.
Clinical Lymphoma|October 23, 2004
Radiometals as payloads for radioimmunotherapy for lymphomaGerald L DeNardo, Stephen J Kennel, Jeffry A Siegel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2005
Direct antilymphoma effects on human lymphoma cells of monotherapy and combination therapy with CD20 and HLA-DR antibodies and 90Y-labeled HLA-DR antibodiesGerald L DeNardo, Evan Tobin, Kaylund Chan, et al.
Bioconjugate Chemistry|January 20, 2005
Characterization of site-specific ScFv PEGylation for tumor-targeting pharmaceuticalsArutselvan Natarajan, Cheng-Yi Xiong, Huguette Albrecht, et al.
Cancer Biotherapy & Radiopharmaceuticals|February 27, 2008
Development of multivalent radioimmunonanoparticles for cancer imaging and therapyArutselvan Natarajan, Cheng-Yi Xiong, Cordula Gruettner, et al.
Bioconjugate Chemistry|March 22, 2007
Synthesis and radiolabeling of selective high-affinity ligands designed to target non-Hodgkin's lymphoma and leukemiaSaphon Hok, Arutselvan Natarajan, Rod Balhorn, et al.
Protein Engineering, Design & Selection : PEDS|June 9, 2006
Development of tumor targeting anti-MUC-1 multimer: effects of di-scFv unpaired cysteine location on PEGylation and tumor bindingCheng-Yi Xiong, Arutselvan Natarajan, Xu-Bao Shi, et al.
Pageof 7